← All stocks

Maze Therapeutics, Inc.

MAZE Net selling
CIK 0001842295 #2211 in the set updated 17 Sep 2026
Bought (120 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$22.57M
$4.01M on a plan · $16.96M straight out of an exercise
Sold at will
$1.60M
17 of 92 sales
Net
−$22.57M
−$1.60M against sales at will

By person

10 insiders · 94 transactions

There is no salary here to measure against. Maze Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Bernstein Harold
President, R&D & CMO
$9.02M (29) scheduled
−$9.02M
0
0.0000%
$0.00
Coloma Jason V
Chief Executive Officer
$5.25M (23) scheduled
−$5.25M
524,131
0.9435%
$13.74M
−21.7%
Dandekar Atul
CSBO
$5.01M (20) scheduled
−$5.01M
32,316
0.0582%
$847.45K
+170.5%
Bachrodt Amy
SVP, Finance
$1.56M (13) scheduled
−$1.56M
12,965
0.0233%
$339.99K
0.0%
Sohn Catherine A.
Director
$1.15M (2) scheduled
−$1.15M
0
0.0000%
$0.00
SCHELLER RICHARD H
Director
$464.03K (1)
−$464.03K
0
0.0000%
$0.00
−100.0%
Courtney Phillips
GC and Corp. Secretary
$104.77K (4)
−$104.77K
7,007
0.0126%
$183.75K
Third Rock Ventures IV, L.P. entity
10% owner
5,424,758
9.77%
$142.26M
+1,643%
Lim Jonathan E
Director
307,956
0.5544%
$8.08M
HOMCY CHARLES J
Director
38,535
0.0694%
$1.01M
+7.2%

Nothing of that kind in this period.

What was left out

Form 4 filings counted 80
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 18
Sales straight out of an exercise 57
Sales at will 17
Transactions with no price 0
Shares from compensation/vesting 9,229,787
History held since 4 Feb 2025